Biotechnology
Pharmaceutical
Biopharmaceutical
MannKind
$1.999876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$1.99
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.15 (-7.04%) Today
+$0.01 (0.51%) After Hours
Why Robinhood?
You can buy or sell MannKind and other stocks, options, ETFs, and crypto commission-free!
About
MannKind Corporation Common Stock, also called MannKind, is a biopharmaceutical company. It focuses on the discovery, development and, commercialization of therapeutic products for diseases, such as diabetes and cancer. Read More The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Westlake Village, CA.
Employees
225
Headquarters
Westlake Village, California
Founded
1991
Market Cap
398.37M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
3.18M
High Today
$2.14
Low Today
$1.93
Open Price
$2.13
Volume
2.90M
52 Week High
$3.04
52 Week Low
$0.94
Collections
Biotechnology
Pharmaceutical
Biopharmaceutical
Health
News
Seeking AlphaMar 23
MannKind - Afrezza Scripts Still Flat Despite Advertising
When the new year arrived, MannKind (MNKD) investors had an air of excitement. The company was flush with $70 million in cash and had announced that it would initiate its largest television advertising campaign and launch a direct to consumer purchase program which would give great pricing on Afrezza to the first 1,000 patients. The advertising started with a bang, logging two consecutive weeks where ad spots topped 300 airings. Since then the campaign has become a bit more modest. The Direct to Consumer p...
Seeking AlphaMar 19
MannKind May Need To Sell Its Only FDA Approved Medication Afrezza To Advance Its Pipeline
To ensure access to Afrezza for adults and children in the future, it may be in MannKind's best interests to sell Afrezza to a committed partner.
Seeking AlphaMar 16
MannKind - Scripts, Sponsorships, Warrants
MannKind (MNKD) investors are quite a happy bunch over the past week or so. The stock has marched above $2.00 per share, and the company seems to have been able to put a bit of news on the table with an Associate Sponsorship of an Indy car participating in the Indianapolis 500. It also appears that the previously undisclosed compound in a deal with United Therapeutics (NASDAQ:UTHR) has been unearthed. Before getting into scripts, let's cover the other news. The undisclosed compound appears to be Adcirca, c...
Price Paid on Robinhood
18% Lower
Right Now
52 Week Low
$0.94
Average Price Paid
$2.42
52 Week High
$3.04
Earnings
-$0.35
-$0.25
-$0.16
-$0.06
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
Expected May 9, Pre-Market